Karen T. Hastings

Lab website
 

Education

• Postdoctoral Fellowship: Immunobiology, Yale University, Howard Hughes Medical Institute, 2006
• Residency: Dermatology, Yale New Haven Hospital, 2004
• Internship: Internal Medicine, Yale New Haven Hospital, 2001
• MD: Harvard University, 2000
• PhD: Immunology, Harvard University, 2000

Publications

• MHC class II on melanoma cells regulates the anti-tumor T cell response.
  Macy AM, Herrmann LM, Thornley EM, Adams AC, Stoll CR, Lancaster JN, Hastings KT. J Immunol. 2026 Jun 7;215(6):vkag158. doi: 10.1093/jimmun/vkag158.

• Immunoediting restricts clonal neoantigens in primary, treatment-naive human tumors.
  Borden ES, Castellano D, Kantzos EA, Hughes A, Leibovit-Reiben Z, Stockard A, Choudhary A, Ma T, Li X, Mangold AR, Gutenkunst RN, LaFleur BJ, Buetow KH, Wilson MA, Hastings KT. Immunity. 2026 Jun 11:S1074-7613(26)00216-5. doi: 10.1016/j.immuni.2026.05.005. Online ahead of print.

• Structural changes from wild-type define tumor-rejecting neoantigens.
  Adams AC, Macy AM, Borden ES, Herrmann LM, Brambley CA, Sonar SA, Ma T, Li X, Hughes A, Roe DJ, Mangold AR, Nikolich JZ, Buetow KH, Wilson MA, Baker BM, Hastings KT. J Immunother Cancer. 2025 Oct 22;13(10):e013148. doi: 10.1136/jitc-2025-013148.

• Towards a transcriptomic biomarker for the classification of melanocytic neoplasms.
  Borden ES, Hastings CT, Prakash N, Kuo T, Tapia E, Yozwiak M, Sagerman P, Vargas de Stefano D, Buetow KH, Wilson MA, Curiel-Lewandrowski C, Chow HS, LaFleur BJ, Hastings KT. PLoS Genet. 2025 Oct 3;21(10):e1011869. doi: 10.1371/journal.pgen.1011869. eCollection 2025 Oct.

• NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic Neoantigens.
  Borden ES, Ghafoor S, Buetow KH, LaFleur BJ, Wilson MA, Hastings KT. J Immunol. 2022 Apr 1;208(7):1813-1827. doi: 10.4049/jimmunol.2100700. Epub 2022 Mar 18.

• More publications on PubMed

Specialties

• American Board of Dermatology